Compare HTT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
High Templar Tech Limited American depositary shares each representing one Class A ordinary share
Current Price
| Metric | HTT | REPL |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.3M | 454.6M |
| IPO Year | 2017 | 2018 |
| Metric | HTT | REPL |
|---|---|---|
| Price | $2.52 | $15.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 152.2K | ★ 7.4M |
| Earning Date | 05-29-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.88 | $1.50 |
| 52 Week High | $3.91 | $15.71 |
| Indicator | HTT | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 66.80 |
| Support Level | $2.34 | $6.99 |
| Resistance Level | $2.59 | N/A |
| Average True Range (ATR) | 0.07 | 1.67 |
| MACD | 0.01 | 0.54 |
| Stochastic Oscillator | 61.70 | 95.48 |
High Templar Tech Ltd is an enabler of financial technology. High Templar is focusing on exploring business opportunities globally to satisfy clients' demand by leveraging its technology know-how and financial service capabilities. The company focus empowering financial institutions with its technological capabilities, helping them improve marketing and operational efficiency and efficiently connect their diverse financial products with online traffic.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.